The −174G>C IL-6 Gene Promoter Polymorphism and Diabetic Microvascular Complications

Abstract

This study examined a possible association of the G>C polymorphism at nucleotide −174 in the promoter region of the interleukin-6 (IL-6) gene (rs1800795) with the prevalence of diabetic complications in 235 patients with type 1 and 498 patients with type 2 diabetes. Genotyping was performed using polymerase chain reaction (PCR) and subsequent cleavage by Nla III restriction endonuclease. Analyzing all diabetic patients together demonstrated that 301 patients (41.1%) carried the GG genotype, 114 (15.6%) the CC genotype, and 318 (43.3%) were heterozygous for the GC genotype. However, there was no correlation of any of the genotypes with the prevalence of diabetic nephropathy or diabetic neuropathy, but subjects with the CC genotype had a significantly higher prevalence of diabetic retinopathy compared to patients with the GC and GG genotype (p=0.016). This association was mainly lost when a logistic regression model was adjusted for diabetes duration (p=0.07). Consistently, a weak but not significant association of the polymorphism with diabetic retinopathy was observed when type 1 and type 2 diabetic patients were analyzed separately (patients with type 1 diabetes: p=0.12; patients with type 2 diabetes: p=0.09). Analogically, no association of the polymorphism was found for diabetic nephropathy or diabetic neuropathy in these groups. In conclusion these data suggest no major influence of the −174G>C variant in the promoter region of the IL-6 gene on the development of microvascular complications in patients with diabetes.

Key words

diabetes - interleukin - diabetic neuropathy - diabetic retinopathy - diabetic nephropathy - rs1800795

References

• 1 Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis.  Diabetologia. 2001;  44 2115-2133
• 2 Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes?.  Diabetologia. 2005;  48 1038-1050
• 3 Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.  Diabetes Care. 2004;  27 813-823
• 4 Graves DT, Kayal RA. Diabetic complications and dysregulated innate immunity.  Front Biosci. 2008;  13 1227-1239
• 5 Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?.  Diabetes. 2005;  54 ((Suppl. 2)) S114-S124
• 6 Uno T, He J, Usui I, Kanatani Y, Bukhari A, Fujisaka S, Yamazaki Y, Suzuki H, Iwata M, Ishiki M, Urakaze M, Haruta T, Ogawa H, Kobayashi M. Long-term interleukin-1alpha treatment inhibits insulin signaling via IL-6 production and SOCS3 expression in 3T3-L1 adipocytes.  Horm Metab Res. 2008;  40 8-12
• 7 Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model.  Rev Physiol Biochem Pharmacol. 2003;  149 1-38
• 8 Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro.  J Clin Endocrinol Metab. 2002;  87 2084-2089
• 9 Fernandez-Real JM, Vayreda M, Ri, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.  J Clin Endocrinol Metab. 2001;  86 1154-1159
• 10 Festa A, D’Agostino Jr R, Tracy RP, Haffner SM. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.  Diabetes. 2002;  51 1131-1137
• 11 Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women.  Diabetes. 2004;  53 693-700
• 12 Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications.  Diabetes Care. 2001;  24 956-957
• 13 Cameron NE, Cotter MA. The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes.  Exp Neurol. 2007;  207 23-29
• 14 Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.  J Clin Invest. 1998;  102 1369-1376
• 15 Georges JL, Loukaci V, Poirier O, Evans A, Luc G, Arveiler D, Ruidavets JB, Cambien F, Tiret L. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Temoin de l’Infarctus du Myocarde.  J Mol Med. 2001;  79 300-305
• 16 Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF. The -597 G-A and -174 G-C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism.  J Clin Endocr Metab. 2002;  87 1134-1141
• 17 Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, Powell JT. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms.  Circulation. 2001;  103 2260-2265
• 18 Cardellini M, Perego L, D’Adamo M, Marini MA, Procopio C, Hribal ML, Andreozzi F, Frontoni S, Giacomelli M, Paganelli M, Pontiroli AE, Lauro R, Folli F, Sesti G. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance.  Diabetes Care. 2005;  28 2007-2012
• 19 Illig T, Bongardt F, Schopfer A, Muller-Scholze S, Rathmann W, Koenig W, Thorand B, Vollmert C, Holle R, Kolb H, Herder C. Kooperative Gesundheitsforschung im Raum Augsburg/Cooperative Research in the Region of Augsburg. Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes.  J Clin Endocrinol Metab. 2004;  89 5053-5058
• 20 Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M. Finnish Diabetes Prevention Study: Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.  Diabetes. 2003;  52 1872-1876
• 21 Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I, Laakso M. The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity.  Diabetes. 2003;  52 558-561
• 22 Mohlig M, Boeing H, Spranger J, Osterhoff M, Kroke A, Fisher E, Bergmann MM, Ristow M, Hoffmann K, Pfeiffer AF. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes.  J Clin Endocrinol Metab. 2004;  89 1885-1890
• 23 Vozarova B, Fernandez-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, Ricart W, Vendrell J, Richart C, Tataranni PA, Wolford JK. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians.  Hum Genet. 2003;  112 409-413
• 24 Kristiansen OP, Nolsoe RL, Larsen L, Gjesing AM, Johannesen J, Larsen ZM, Lykkesfeldt AE, Karlsen AE, Pociot F, Mandrup-Poulsen T, DIEGG, DSGD. Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females.  Hum Mol Genet. 2003;  12 1101-1110
• 25 Jahromi MM, Millward BA, Demaine AG. A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus.  J Interferon Cytokine Res. 2000;  20 885-888
• 26 Eerligh P, Koeleman BP, Dudbridge F, Jan Bruining G, Roep BO, Giphart MJ. Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes.  Genes Immun. 2004;  5 36-40
• 27 Testa R, Olivieri F, Bonfigli AR, Sirolla C, Boemi M, Marchegiani F, Marra M, Cenerelli S, Antonicelli R, Dolci A, Paolisso G, Franceschi C. Interleukin-6-174 G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients.  Diabetes Res Clin Pract. 2006;  7 299-305
• 28 Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC, Malaponte G. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease.  J Clin Pathol. 2006;  59 211-215
• 29 Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, Tiberghien P, Chalopin JM, Saas P, Ducloux D. IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation.  J Am Soc Nephrol. 2006;  17 2333-2340
• 30 Herbert A, Liu C, Karamohamed S, Liu J, Manning A, Fox CS, Meigs JB, Cupples LA. BMI modifies associations of IL-6 genotypes with insulin resistance: the Framingham Study.  Obesity. 2006;  14 1454-1461
• 31 Huth C, Heid IM, Vollmert C, GiegerC, Grallert H, Wolford JK, Langer B, Thorand B, Klopp N, Hamid YH, Pedersen O, Hansen T, Lyssenko V, Groop L, Meisinger C, Döring A, Loewel H, Lieb W, Hengstenberg C, Rathmann W, Martin S, Stephens JW, Ireland H, Mather H, Miller GJ, Stringham HM, Boehnke M, Tuomilehto J, Boening H, Möhlig M, Spranger J, Pfeiffer A, Wernstedt I, Niklason A, Lopez-Bermejo A, Fernandez-Real JM, Hanson RL, Gallart L, Vendrell J, Tsiavou A, Hatziagelaki E, Humphries SE, Wichmann HE, Herder C, Illig T. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants’ data from 21 studies.  Diabetes. 2006;  55 2915-2921
• 32 World Health Organization . Diabetes Mellitus: Report of a WHO Study Group. , Geneva World Health Org. (Tech. Rep. Ser., no. 727), 1985
• 33 DCCT Research Group . Factors in the development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of diabetic control and complications trials.  Diabetes. 1999;  37 471-481
• 34 Humpert PM, Papadopoulos G, Schaefer K, Djuric Z, Konrade I, Morcos M, Nawroth PP, Bierhaus A. sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes.  Horm Metab Res. 2007;  39 899-902
• 35 Rudofsky Jr G, Schrödter A, Voron’ko OE, Schlotterer A, Humpert PM, Tafel J, Nawroth PP, Bierhaus A, Hamann A. Promoter polymorphisms of UCP1, UCP2, and UCP3 are not associated with diabetic microvascular complications in type 2 diabetes.  Horm Metab Res. 2007;  39 306-309
• 36 Marso SP, House JA, Hopkins PJ. Increase in interleukin-6 following arterial injury is related to insulin resistance, the -174G→C polymorphism and complex plaque morphology.  Int J Immunogenet. 2006;  33 347-354
• 37 Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.  Am J Ophthalmol. 2002;  133 70-77
• 38 Nakamura N, Hasegawa G, Obayashi H, Yamazaki M, Ogata M, Nakano K, Yoshikawa T, Watanabe A, Kinoshita S, Fujinami A, Ohta M, Imamura Y, Ikeda T. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy.  Diabetes Res Clin Pract. 2003;  61 93-101
• 39 Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, Sayed AA, Andrassy M, Schiekofer S, Schneider J, Schulz J, Heuss D, Neundörfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M, Häring HU, Schleicher E, Stern DM, Kasper M, Arnold B, Nawroth PP. Loss of pain perception in diabetic neuropathy is dependent on a receptor of the immune globulin superfamily.  J Clin Invest. 2004;  114 1741-1751
• 40 Haslbeck KM, Bierhaus A, Erwin S, Kirchner A, Nawroth P, Schlotzer U, Neundorfer B, Heuss D. Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy.  Muscle Nerve. 2004;  29 853-860
• 41 Twining CM, Sloane EM, Milligan ED, Chacur M, Martin D, Poole S, Marsh H, Maier SF, Watkins LR. Peri-sciatic proinflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in rats.  Pain. 2004;  110 299-309
• 42 Lanza GA, Pitocco D, Navarese EP, Sestito A, Sgueglia GA, Manto A, Infusino F, Musella T, Ghirlanda G, Crea F. Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade.  Eur Heart J. 2007;  28 814-820
• 43 González-Clemente JM, Vilardell C, Broch M, Megia A, Caixàs A, Giménez-Palop O, Ri, Simón I, Martínez-Riquelme A, Arroyo J, Mauricio D, Vendrell J. Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes.  Eur J Endocrinol. 2007;  157 31-38
• 44 Hoekzema R, Verhangen C, van Haren M, Kijlstra A. Endotoxin-induced uveitis in the rat. The significance of intraocular interleukin-6.  Inves Ophtalmol Vis Sci. 1992;  33 532-539
• 45 Cohen T, Nahari D, Cerem LW, Neufeld G, Levi B. Interleukin 6 induces the expression of vascular endothelial growth factor.  J Biol Chem. 1996;  271 736-741
• 46 Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, Macchioni P, Bajocchi G, Catanoso MG, Pulsatelli L, Consonni D, Salvarani C. Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica.  J Rheumatol. 2006;  33 703-708
• 47 Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, Rumpold H, Gerdov M, Mannhalter C, Prager R, Irsigler K, Wagner OF. Association of low-grade inflammation with nephropathy in type 2 diabetes patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines.  Exp Clin Endocrinol Diabetes. 2007;  115 38-41

Correspondence